Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07115017 · ClinicalTrials.gov registry record

This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.

A clinical trial of Multiple Sclerosis, sponsored by Washington University School of Medicine.

Recruiting
Registry status
80
Enrollment target
1
Study location

NCT07115017: Recruiting study of Multiple Sclerosis, sponsored by Washington University School of Medicine.

NCT07115017 is a study of Multiple Sclerosis that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 80 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07115017, a study of Multiple Sclerosis, is actively recruiting participants, sponsored by Washington University School of Medicine.

RECRUITING
Registry status
80 participants
Enrollment target
1
Study location

Study Summary

This study involves a Positron Emission Tomography (PET) scan using a new investigational radioactive tracer, \[18F\]-FZTA, to detect inflammation in the brain. The tracer will be tested in healthy younger adults and individuals with Multiple Sclerosis.

Primary Outcome

To test the hypothesis that specific binding of \[18F\]-FZTA is elevated in participants with Multiple Sclerosis compared to healthy normal control participants.

Conditions Studied

Interventions

  • DRUG [18F] FZTA

Study Locations (1)

Missouri

  • Washington University in St. Louis - St Louis

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2025-08-22
Est. Completion 2029-12

What NCT07115017 shows while recruiting

NCT07115017 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which [18F] FZTA is the first listed.

NCT07115017 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT07115017 about?

NCT07115017 is a clinical study titled "This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.". This study involves a Positron Emission Tomography (PET) scan using a new investigational radioactive tracer, \[18F\]-FZTA, to detect inflammation in the brain. The tracer will be tested in healthy younger adults and individuals with Multiple Sclerosis.

What is the current status of trial NCT07115017?

This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2025-08-22. Estimated completion is 2029-12.

What conditions does trial NCT07115017 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT07115017?

The interventions under investigation include: [18F] FZTA (DRUG).

Who is sponsoring clinical trial NCT07115017?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07115017 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07115017's enrollment target sits among peer trials

80 141st of 315 higher than 173 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07115017, the US trial registry maintained by the National Library of Medicine. NCT07115017 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.